RBC Capital Starts Forward Pharma (FWP) at Outperform

RBC Capital initiated coverage on Forward Pharma (NASDAQ: FWP) with an Outperform rating and a price target of $33.00.

Analyst Michael J. Yee said, "We are initiating coverage of Forward Pharma (FWP) with an Outperform, Speculative Risk rating and a $33 price target. We think there are numerous upside scenarios: 1) key patent positions with royalties; 2) approval for FWP's oral FP187 as a $1B+ drug in multiple sclerosis; 3) as a $500M+ psoriasis drug; or 4) potential takeout by various MS/immunology players."

For an analyst ratings summary and ratings history on Forward Pharma click here. For more ratings news on Forward Pharma click here.

Shares of Forward Pharma closed at $21.05 yesterday.

You May Also Be Interested In

• UBS Downgrades DiaSorin SpA (DIA:IM) (DSRLF) to Sell
• Jefferies Downgrades Computershare Limited (CPU:AU) (CMSQY) to Hold
• Erasca Inc (ERAS) PT Raised to $22 at H.C. Wainwright